Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease

Transplant Infectious Disease

Volumn 14, Issue 5, 2012, Pages 488-495

  Eurich, D ^a   Boas Knoop, S ^a   Yahyazadeh, A ^a   Neuhaus, R ^a   Somasundaram, R ^a   Ruehl, M ^a   Puhl, G ^a   Neuhaus, P ^a   Neumann, U P ^b   Bahra, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Acute cellular rejection; Genetic variants; HCV; Liver transplantation; MBL 2

Indexed keywords

ALPHA INTERFERON; AMANTADINE; BETA INTERFERON; MANNOSE BINDING LECTIN 2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SILIBININ;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MBL 2 GENE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

FEMALE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MANNOSE-BINDING LECTIN; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 84867631834     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00747.x     Document Type: Article

References (46)

1. Rossol S. [Chronic HCV infections. A model disease for therapy, economics and social-medical aspects]. Gesundheitswesen 2007; 69: 146-150.
2. Iadonato SP, Katze MG. Genomics: hepatitis C virus gets personal. Nature 2009; 461: 357-358.
3. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231.
4. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl 1): S59-S67.
5. Berenguer M. Recurrent allograft disease: viral hepatitis. Acta Gastroenterol Belg 2005; 68: 337-346.
6. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.
7. Friedman SL. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol 1997; 32: 424-430.
8. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
9. Ben-Ari Z. Role of cytokine gene polymorphism in recurrent HCV infection after liver transplantation. Liver Transpl 2006; 12: 1723-1724.
10. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833.
11. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Laundy GJ. Human cytokine gene nucleotide sequence alignments, 1998. Eur J Immunogenet 1998; 25: 83-265.
12. Ben-Ari Z, Tambur AR, Pappo O, et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 2006; 81: 392-397.
13. Eurich D, Bahra M, Boas-Knoop S, et al. Transforming growth factor β1 polymorphisms and graft fibrosis progression after liver transplantation for hepatitis C virus-induced liver disease. Liver Transpl 2011; 17 (3): 279-288.
14. Larsen F, Madsen HO, Sim RB, Koch C, Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004; 279: 21302-21311.
15. Segat L, Fabris A, Padovan L, et al. MBL2 and MASP2 gene polymorphisms in patients with hepatocellular carcinoma. J Viral Hepat 2008; 15: 387-391.
16. Sasaki K, Tsutsumi A, Wakamiya N, et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 2000; 35: 960-965.
17. Matsushita M, Hijikata M, Ohta Y, et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. Arch Virol 1998; 143: 645-651.
18. Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol 2005; 15: 235-268.
19. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-3020.
20. Worthley DL, Johnson DF, Eisen DP, et al. Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clin Infect Dis 2009; 48: 410-417.
21. Butler GS, Sim D, Tam E, Devine D, Overall CM. Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency. J Biol Chem 2002; 277: 17511-17519.
22. Crosdale DJ, Ollier WE, Thomson W, et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. Eur J Immunogenet 2000; 27: 111-117.
23. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
24. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649-654.
25. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
26. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-47.
27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
28. Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14.
29. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
30. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
31. Eurich D, Boas-Knoop S, Ruehl M, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17 (3): 289-298.
32. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2011; 139 (5): 1577-1585.
33. Bataller R. [Genetic polymorphisms and liver diseases]. Gastroenterol Hepatol 2003; 26: 307-309.
34. Wasowska BA. Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res 2010; 47 (1-3): 25-44.
35. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006; 67: 247-256.
36. Fildes JE, Shaw SM, Walker AH, et al. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation. J Heart Lung Transplant 2008; 27: 1353-1356.
37. Alves Pedroso ML, Boldt AB, Pereira-Ferrari L, et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol 2008; 152: 258-264.
38. Berger SP, Roos A, Mallat MJ, Fujita T, de Fijter JW, Daha MR. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant 2005; 5: 1361-1366.
39. Rantala A, Lajunen T, Juvonen R, et al. Mannose-binding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J Infect Dis 2008; 198: 1247-1253.
40. Fiane AE, Ueland T, Simonsen S, et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J 2005; 26: 1660-1665.
41. Hove WR, van Hoek B, Bajema IM, Ringers J, van Krieken JH, Lagaaij EL. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 2003; 9: 552-556.
42. Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16 (7): 895-908.
43. Bouwman LH, Roos A, Terpstra OT, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408-414.
44. Cervera C, Balderramo D, Suarez B, et al. Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transpl 2009; 15: 1217-1224.
45. Brooks BK, Levy MF, Jennings LW, et al. Influence of donor and recipient gender on the outcome of liver transplantation. Transplantation 1996; 62: 1784-1787.
46. Rustgi VK, Marino G, Halpern MT, Johnson LB, Umana WO, Tolleris C. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl 2002; 8: 514-518.